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Over the past decade, the classifications
and volume of non-coding RNA (ncRNA)
transcripts have grown profoundly,
spurred by transcriptomic sequencing
efforts (Bartel, 2009; Guttman et al., 2009;
Djebali et al., 2012). This has identified an
array of human disorders associated with
some degree of ncRNA dysregulation (Taft
et al., 2010), prompting an expanding
need to characterize ncRNA expression in
targeted tissues. Brain disorders, including
neurodegenerative and psychiatric dis-
ease, have increasingly been the subject of
ncRNA profiling studies (Kocerha et al.,
2009a,b; Beveridge et al., 2010; Im and
Kenny, 2012). The technology to probe
for ncRNA expression, however, varies,
depending on the class of transcripts
to be examined. Arguably, to date, the
resources to assess microRNA (miRNA)
expression are the most comprehensive,
spanning from classic hybridization arrays
to real-time PCR arrays. However, with
the discovery of long ncRNAs (lncRNAs)
in the brain, such as natural antisense
transcripts (NATs) and large intergenic
non-coding (Linc) RNAs (Guttman et al.,
2009; Modarresi et al., 2012), the access to
new technology for examination of those
transcripts is also expanding.
One of the challenges with the emerg-
ing field of ncRNAs is the frequent updates
to the current database of annotated tran-
scripts and occasional changes in nomen-
clature, making it essential to keep current
with available sequence information. For
example, the miRBase server, which con-
tains all annotated miRNAs, has already
been updated through 19 different ver-
sions to date. Importantly, these updates
can include addition or deletion of tran-
scripts due to various reasons. Technology
suppliers usually lag behind databases
with their ncRNA platforms, although
some have the capacity to include cus-
tom content if required for a particular
study. The fluctuation in transcript anno-
tation is also important to consider in
the context of lncRNAs, as fixed platforms
take longer to accommodate changes in
this rapidly emerging genomic dimen-
sion. For this reason, RNA sequencing
(RNA-Seq) approaches that don’t rely on
a priori information and annotation have
the advantage of flexibility. This flexi-
bility, however, comes at some expense
in terms of accessibility, analysis, and
quantification.
Despite considerable advances in
ncRNA analysis, there remains techni-
cal challenges and key differences between
platforms and approaches that may add
further variation to an area already subject
to heterogeneity. For example, post-
mortemmiRNAprofiling in schizophrenia
has revealed significant changes associated
with the disorder (Perkins et al., 2007;
Beveridge et al., 2008, 2010; Santarelli
et al., 2011). While compelling, the
correspondence between different labo-
ratories has not been as high as expected
(Beveridge and Cairns, 2012). This could
be a feature of disease heterogeneity or the
dynamics of miRNA function and distri-
bution in the brain, or a consequence of
variation in cytoarchitecture and cellular
composition. Some of these parameters
will be controlled better in larger cohorts,
and by screening multiple sub-regions
or through more precise sampling. Other
sources of variation and artifact may reside
at the level of molecular analyses, includ-
ing technical variation between various
platforms and data analysis techniques,
whether they be hybridization, amplifi-
cation, or sequencing based. All of these
approaches will have some bias and make
some assumptions based on the normal-
ization strategy. For example, all three
of these approaches usually entail some
degree of amplification, which is notori-
ous for introducing bias. The extent of
amplification will depend both on the
sensitivity of the instrumentation and the
amount of RNA that can be devoted to
ncRNA analysis. As the cellular speci-
ficity is increased, the need for further
amplification or pre-amplification also
increases. Pre-amplification may result in
detection of non-neuronal ncRNAs in the
brain tissues analyzed, therefore, accu-
rate interpretation of the results is critical
to avoid the over interpretation of con-
taminating template. There is also other
bias introduced by methodologies such
as RNA-Seq that require ligation of link-
ers for cDNA library construction. Even
the type of RNA extraction can influ-
ence results, particularly with small RNAs
that have large sequence dependent dif-
ferences in physicochemical properties
that affect their affinity for purification
matrices or capacity for precipitation. For
example, the standard Trizol preparation
of small RNA has been shown to be influ-
enced by the magnesium concentration
(Kim et al., 2012). ncRNA expression may
also vary significantly between distinct
brain regions, either with or without the
presence of neurological pathogenesis.
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Again, these differences can only be
appreciated by more widespread collection
and analysis of disease associated tissues.
RNA-Seq is contributing to significant
discoveries in neuroscience research. One
of the key advantages of this approach
is that poorly characterized RNA vari-
ants, particularly of the non-coding vari-
ety that lack comprehensive annotation,
are now captured and can be analyzed.
Previously, these molecules were only
seen at great expense on genome tiling
arrays and a few custom non-coding
arrays. This technology has the poten-
tial to make a tremendous impact in the
ncRNA world as they emerge for the first
time with an equal billing as the cod-
ing transcripts. This technology, how-
ever, is also subject to some limitations
that need to be considered for experi-
mental design, in addition to the issue
of ligation, amplification, and normaliza-
tion bias mentioned already. Firstly, there
are no one-size-fits all strategy for ncR-
NAs. Small RNAs, such as miRNA, need
to be fractionated and treated separately
to their longer counterparts. Standard
RNA-Seq, also poly-A selection during
library preparation and as such, will not
enrich for RNA transcribed by pol III
promoters and other intergenic promot-
ers. Total RNA-Seq requires a ribosomal
RNA depletion step, and to fully appre-
ciate the influence of NATs it may be
necessary to use strand-specific RNA-seq.
Even more selection may be necessary
to find rare non-coding transcripts. For
example, ncRNAs were recently found in
“gene deserts” after targeted enrichment
using tiling arrays (Mercer et al., 2011).
With more small RNA analysis employ-
ing sequencing, depth is also important
for identifying miRNA variants (isomiRs)
and other variants produced through RNA
editing (Peng et al., 2012). Overall, a
detailed comparison of ncRNA sequences
in control vs. diseased patients may open
the door to identifying new transcrip-
tomic mechanisms provoked through dis-
tinct human genetic anomalies. These
advances in RNA technology and analy-
sis hold great promise for the discovery of
new ncRNA biomarkers and therapeutics
for brain disorders.
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